咳嗽·感冒·過敏:大流行病後的全球CCA的機會的闡明

Cough, Cold & Allergy: Unravelling CCA Opportunities in a Post-Pandemic World

出版日期: 2025年07月31日 | 出版商:

Nicholas Hall Group of Companies | 英文 | 訂單完成後即時交付

價格

簡介目錄

咳嗽、感冒和過敏是2024年全球CHC（慢性中樞神經系統疾病）類別中成長最慢的。雖然許多產品的需求是由季節性疾病的流行和嚴重程度所驅動的，但行銷人員正在尋找能夠推動全年銷售的新利基市場，例如高空氣污染水平。在持續的成分限制下， "天然" 趨勢正在推動新產品開發活動，但消費者也在尋求能夠解決多種症狀並快速緩解的 "一體化" 產品。隨著產品轉換活動繼續成為成長和創新的關鍵驅動力，過敏藥物預計將蓬勃發展。隨著免疫相關產品（包括咳嗽和感冒品牌及補充劑）的需求降溫，行銷人員可能需要尋找新的利基市場。

本報告探討並分析了全球咳嗽、感冒和過敏市場，提供按國家和類別劃分的銷售數據、各個品牌的表現以及截至 2029 年和 2034 年的預測。

深入探討 10 個獨立市場

巴西
印度
波蘭
中國

法國
德國
義大利
日本

英國
美國

選擇作為簡略的附加的市場

澳洲

加拿大

墨西哥

俄羅斯

An in-depth exploration of the CHC Cough, Cold & Allergy market globally, including Cough remedies, Systemic cold & flu, Allergy remedies, Decongestants, Sore throat remedies and more
Immunity-related VMS - including vitamin C, zinc and immune supplements - also investigated
Very latest year-end 2024 sales from the just-published DB6, our dedicated CHC sales database, plus historical growth rates back to 2020
Internet & mail order channel sales for every market profiled
Coverage of marketer activity, highlighting strategies and success factors, sales, NPD activity and consumer & HCP promotion
Coverage of 14 major markets from around the world, with topline sales, brand performances, latest developments, launches and promotional campaigns
A look to the future includes long-term forecast sales for all categories and countries to 2029 & 2034, plus the most up-to-date short-term forecasts (to 2025 & 2026)

Cough, Cold & Allergy was the slowest-growing CHC category globally in 2024, as systemic cold & flu and cough remedies progressed at a modest rate, but the outlook is steady, with growth trends returning to a more normal level. While demand for many products is dependent on incidence and severity of seasonal pathologies, marketers are identifying new niches to drive year-round sales such as high levels of air pollution. As restrictions continue on various ingredients, the trend towards "naturals" has fuelled NPD activity, but consumers are also demanding multi-symptom, fast-acting or "all-in-one" products. Allergy remedies look set for better growth, as switch activity remains a robust influencer of growth and innovation in the future. As demand for immunity-related products cools (among cough & cold brands and supplements), marketers may need to find new niches.

This report will investigate pressing issues affecting the global CCA market, digging into multiple areas of interest and highlighting inherent opportunities. Examining ten core markets in detail (and additional key markets in brief), analysing brand performances and launch activity, our CCA report will investigate the untapped potential in this CHC category.

The report features the latest end-2024 sales data from our dedicated DB6 database, including topline historical sales globally, by country and category, as well as individual brand performances, and long-term forecasts to 2029 and 2034. Coverage extends to the online channel, with internet & mail order sales of CCA included in the topline and a dedicated section in each country profile.

Diving into the factors affecting individual Cough, Cold & Allergy markets, from consumer trends and regulatory changes to A+P campaigns and new product launch activity, this report sheds light on trends & developments across 10 in-depth country profiles with insights and predictions, as well as shorter profiles of other key markets.

"1" selected markets only.

"2" sales tracked under VMS in DB6 (vitamin C, zinc, immune supplements).

Assessing the short-term outlook, the report includes full year 2025 & 2026 forecasts for all categories in each market profiled.

With launch activity in CCA picking up again after several years of decline, has the impetus shifted from quantity to quality? New product development is explored across markets, including Rx-to-OTC switches, delivery format innovations, new benefits and more.

Key questions investigated in this report:

How do key growth drivers, consumer choices and competitive landscape differ from market to market?
Which marketers and brands have proved most successful?
Has NPD benefited the CCA market and can it be a future growth driver?
What are the opportunities for e-commerce and digital marketing for CCA brands?
Can new niches and underserved demographics be identified?
How is the adjacent category of immunity-related supplements faring?
What is the outlook for CCA and where can opportunities be found?

10 individual markets profiled in depth: